I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

CHDI 2025

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

Feb 27 / Roche and Genentech
Allele-selective lowering in HD: From bench to bedside
In this presentation we will share for the first time preclinical data from our allele-selective huntingtin-lowering program, HTT SNP ASO. In order to accurately identify individuals who could benefit from this approach, we have developed a novel SNP phasing assay capable of identifying distant intronic and exonic SNPs in phase with the expanded CAG mutation, paving the way for identifying multiple SNPs in parallel.

Sign up or login to unlock the full suite of MEDICALLY features

Feb 26 / Roche and Genentech
Development of a long-read phasing assay for allele-specific patient inclusion for Roche HTT SNP ASO program
This poster describes the development of an innovative assay that allows phasing of distant intronic SNPs with the expanded CAG repeat that causes Huntington’s disease (HD). The assay is a prerequisite for selecting individuals with HD who could benefit most from allele-selective antisense oligonucleotide treatment.

Sign up or login to unlock the full suite of MEDICALLY features

Feb 24 / Roche and Genentech
Towards disease modifying treatments in HD: An update from Roche
In this presentation we share Roche's and Spark's commitment in HD which expand from therapeutic development of diverse approaches to tacke HD to efforts to contribute more broadly to the HD community and advance scientific knowledge and understanding of the pathophysiology of the disease. These range from running observational studies to pioneering data sharing and harmonisation efforts in partnership with HD-RSC and CHDI.
05:00 PM
Duration 20mins Palm Springs
Towards disease modifying treatments in HD: An update from Roche
Peter McColgan

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
09:00 PM
Duration 180mins California, US
Development of a long-read phasing assay for allele-specific patient inclusion for Roche HTT SNP ASO program
Anna Rautanen

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:00 PM
Duration 25mins Palm Springs
Allele-selective lowering in HD: From bench to bedside
Peter McColgan

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar